Inactive Instrument

Highlights CTI BioPharma Corp Nasdaq

Equities

US12648L1061

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2023	DRI Healthcare Trust Receives US$54.8 Million in Debt Repayment	MT
2023	DRI Healthcare Trust Brief: Announcing US$54.8 Million Debt Repayment from CTI BioPharma Corp.	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

DRI Healthcare Trust Receives US$54.8 Million in Debt Repayment	23-06-26	MT
Sobi Wraps Up $1.7 Billion Acquisition of CTI BioPharma	23-06-26	MT
Swedish Orphan Biovitrum Completes Tender for CTI BioPharma	23-06-25	MT
Swedish Orphan Biovitrum AB (OM:SOBI) completed the acquisition of CTI BioPharma Corp. from a group of shareholders.	23-06-25	CI
Sweden's Sobi Initiates Tender Offer to Acquire CTI BioPharma	23-05-25	MT
CTI BioPharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
CTI BioPharma Shares Soar After Sobi's $1.7 Billion Takeover Announcement	23-05-10	MT
Sweden's Sobi to Buy Hematology-focused CTI Biopharma for $1.7 Billion	23-05-10	MT
Sweden's SOBI makes $1.7 billion offer to buy CTI BioPharma	23-05-10	RE
Swedish Orphan Biovitrum AB (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. from a group of shareholders for $1.2 billion.	23-05-09	CI
CTI BioPharma's Q4 Loss Narrows	23-03-06	MT
CTI BioPharma Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-06	CI
CTI BioPharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-06	CI
CTI BioPharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-07	CI
CTI BioPharma Corp. Announces Presentation of New Anemia Benefit Data from Pacritinib Program At the Society of Hematologic Oncology Tenth Annual Meeting	22-09-21	CI
CTI BioPharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-08	CI
CTI BioPharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
National Comprehensive Cancer Network Recommends CTI BioPharma Corp.'s VONJO™ for the Treatment of Myeloproliferative Neoplasms	22-04-14	CI
CTI BioPharma's Q4 Net Loss Widens; Shares Drop Friday Afternoon	22-04-01	MT
CTI BioPharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CTI BioPharma Corp Nasdaq

Equities

US12648L1061

Highlights

Filters